Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology CRISPR drug development FDA Pharmaceuticals

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Pfizer accused of major tax-dodging scheme - 13 days ago How the race for the next obesity drug is shaping up - about 1 month ago The view from overseas on tumult in U.S. science - about 2 months ago The biotech news stories you need to read today - about 2 months ago The biotech news stories we’re keeping an eye on - 3 months ago Eli Lilly seeks to join lawsuit on compounded drugs - 3 months ago The biotech news roundup to start your week - 5 months ago The biotech news you need to read today - 5 months ago Element Biosciences raises another massive round - 9 months ago The biotech news you missed this week - 9 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 11 months ago How resurrecting extinct species might impact medicine - about 1 year ago Lawmakers want to add more Chinese biotechs to defense list - about 1 year ago The Senate health committee looks into its first subpoena in 40 years - about 1 year ago The biotech updates you need to read today - over 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - over 1 year ago FDA chastens pet companies over antibiotics - over 1 year ago The biotech news you missed from the weekend - over 1 year ago Novartis is building a new radioligand plant in China - over 1 year ago Today’s biotech news roundup, in under 800 words - over 1 year ago A new algorithm unveils CRISPR ‘treasure trove’ - over 1 year ago These are the need-to-know biotech stories from this weekend - over 1 year ago XBI biotech index rises, giving investors a shred of hope - over 1 year ago Shrinking Covid vaccine sales has Moderna course-correcting - over 1 year ago Your Monday morning biotech news roundup - over 1 year ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - over 1 year ago Want a biotech buyout? Target cancer - over 1 year ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Biotechs emerging from stealth take aim at pharma’s prime targets - 17 days ago 4 companies to watch in the accelerating gene editing race - 3 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 6 months ago Who’s winning in biotech’s tight market? - 7 months ago Astellas’ science chief on the leap into new technologies - about 1 year ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - over 1 year ago
3	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech is in a dark place - about 2 months ago A biotech’s binary bet ends badly - 10 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 12 months ago STAT+: Weed for weight loss, and more from Biotech Land - about 1 year ago
4	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - about 2 months ago This week in biotech earnings so far - 2 months ago East Asians under-represented in biopharma leadership - 3 months ago A key decision on compounding is expected this week - 4 months ago Gameto says first baby born using new stem-cell tech - 4 months ago BioMarin’s big day today - 7 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 11 months ago
5	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - about 2 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 11 months ago 4 offbeat biotechs making a splash in the life sciences - 12 months ago What’s old is new: The revival of a one-time radiotherapy cancer treatment - about 1 year ago These biotech hotspots are ripe for IPOs - about 1 year ago Black Diamond looks to outwit cancer mutations - about 1 year ago
6	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 5 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 5 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 6 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 8 months ago A biotech dousing ‘fires’ in the brain that plagued a bestselling author - 8 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 9 months ago Protein power: a biotech mining viruses to fight disease - 9 months ago 3 up-and-coming US biotech hotspots - 11 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 12 months ago Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future - about 1 year ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery - over 1 year ago This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain - over 1 year ago How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times - over 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago A new delivery method muscling its way into the RNA space - over 1 year ago
7	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	The biotech updates you need to read this morning - 6 months ago
8	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	The Best Biotech Stock to Invest $1,000 in Right Now - 10 months ago
9	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: How biotech investors spot opportunity when stocks are down — and up - about 1 year ago STAT+: Biotech incubator Curie.Bio graduates its first startup - over 1 year ago STAT+: Life science investors close nearly $6 billion in new funds - over 1 year ago
10	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - about 1 year ago

Journalists covering Biotech Spotlight